Alison Kanski

Analysis of 7,500 patients showed one-third had potentially actionable mutations and 10 percent were misdiagnosed, prompting calls for greater NGS use in this setting.

Bolstered by the success of KRAS G12C inhibitors in lung cancer, smaller firms are developing drugs for a range of other KRAS-mutated cancers and trying to anticipate resistance. 

The company reported positive data from the Phase II RAGNAR study, in which Balversa showed activity across 14 different tumor types.

The company is tackling the challenges in pediatric cancer drug development by repurposing drugs and efficiently conducting trials.

Counter to a prior study, recurrent ovarian cancer patients with BRCA1/2 mutations or a BRCAness phenotype did not benefit on single-agent Yondelis versus chemo.

The companies have pan-cancer ambitions for these drugs, and the data presented at ASCO are starting to show activity in specific NRG1 fusion-positive tumor types.

The drugmaker said it will push to add the latest CNS activity data presented at ASCO to its regulatory application already with the FDA.

Seven years of follow-up data showed that Ibrance plus letrozole didn't significantly improve survival compared to letrozole alone in advanced ER-positive breast cancer.

However, in the Phase III PARADIGM trial, there was no difference in survival between the two arms when researchers focused only on patients with right-sided tumors.

Researchers will explore combination treatment strategies with Mirati's adagrasib that can help patients overcome both primary and acquired resistance.